EP4099992A4 - Nouvelles formulations de cannabinoïdes et leur utilisation pour le traitement de la myélite flasque aiguë - Google Patents

Nouvelles formulations de cannabinoïdes et leur utilisation pour le traitement de la myélite flasque aiguë

Info

Publication number
EP4099992A4
EP4099992A4 EP21751396.9A EP21751396A EP4099992A4 EP 4099992 A4 EP4099992 A4 EP 4099992A4 EP 21751396 A EP21751396 A EP 21751396A EP 4099992 A4 EP4099992 A4 EP 4099992A4
Authority
EP
European Patent Office
Prior art keywords
formulations
treatment
novel cannabinoids
acute flaccid
myelitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21751396.9A
Other languages
German (de)
English (en)
Other versions
EP4099992A1 (fr
Inventor
Philip Arlen
Stella K Vnook
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Diverse Biotech Inc
Original Assignee
Diverse Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diverse Biotech Inc filed Critical Diverse Biotech Inc
Publication of EP4099992A1 publication Critical patent/EP4099992A1/fr
Publication of EP4099992A4 publication Critical patent/EP4099992A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
EP21751396.9A 2020-02-08 2021-02-08 Nouvelles formulations de cannabinoïdes et leur utilisation pour le traitement de la myélite flasque aiguë Pending EP4099992A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062971956P 2020-02-08 2020-02-08
PCT/US2021/017042 WO2021159058A1 (fr) 2020-02-08 2021-02-08 Nouvelles formulations de cannabinoïdes et leur utilisation pour le traitement de la myélite flasque aiguë

Publications (2)

Publication Number Publication Date
EP4099992A1 EP4099992A1 (fr) 2022-12-14
EP4099992A4 true EP4099992A4 (fr) 2024-03-06

Family

ID=77200742

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21751396.9A Pending EP4099992A4 (fr) 2020-02-08 2021-02-08 Nouvelles formulations de cannabinoïdes et leur utilisation pour le traitement de la myélite flasque aiguë

Country Status (3)

Country Link
US (1) US20230157992A1 (fr)
EP (1) EP4099992A4 (fr)
WO (1) WO2021159058A1 (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH695661A5 (de) * 2001-03-06 2006-07-31 Forsch Hiscia Ver Fuer Krebsfo Pharmazeutische Zusammensetzung.
GB2450741A (en) * 2007-07-05 2009-01-07 Gw Pharma Ltd Cannabinoid containing plant extracts in the treatment of inflammatory bowel disease
GB2542797A (en) * 2015-09-29 2017-04-05 Gw Pharma Ltd Use of cannabinoids in the treatment of inflammatory skin diseases
US10765658B2 (en) * 2016-06-22 2020-09-08 Mastix LLC Oral compositions delivering therapeutically effective amounts of cannabinoids

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BITNUN ARI ET AL: "Acute Flaccid Paralysis and Enteroviral Infections", CURRENT INFECTIOUS DISEASE REPORTS, SPRINGER US, NEW YORK, vol. 20, no. 9, 29 June 2018 (2018-06-29), XP037137605, ISSN: 1523-3847, [retrieved on 20180629], DOI: 10.1007/S11908-018-0641-X *
DOWNEY RACHEL ET AL: "Acute Flaccid Myelitis Among Hospitalized Children in Texas, 2016", PEDIATRIC NEUROLOGY, ELSEVIER SCIENCE, NL, vol. 106, 7 February 2020 (2020-02-07), pages 50 - 55, XP086129584, ISSN: 0887-8994, [retrieved on 20200207], DOI: 10.1016/J.PEDIATRNEUROL.2020.01.007 *
JUN ZUO ET AL: "Discovery of Structurally Diverse Small-Molecule Compounds with Broad Antiviral Activity against Enteroviruses", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 60, no. 3, 1 March 2016 (2016-03-01), US, pages 1615 - 1626, XP055694837, ISSN: 0066-4804, DOI: 10.1128/AAC.02646-15 *
MCGREW HANNAH ET AL: "Updates on Novel Illicit Drugs: What Practitioners Should Be Aware Of", JOURNAL OF EMERGENCY NURSING, vol. 43, no. 6, 2017, pages 591 - 592, XP085258395, ISSN: 0099-1767, DOI: 10.1016/J.JEN.2017.07.012 *
See also references of WO2021159058A1 *
THEROUX LIANA M ET AL: "Acute Transverse and Flaccid Myelitis in Children", CURRENT TREATMENT OPTIONS IN NEUROLOGY, SPRINGER US, NEW YORK, vol. 21, no. 12, 3 December 2019 (2019-12-03), XP036963350, ISSN: 1092-8480, [retrieved on 20191203], DOI: 10.1007/S11940-019-0603-0 *

Also Published As

Publication number Publication date
WO2021159058A1 (fr) 2021-08-12
EP4099992A1 (fr) 2022-12-14
US20230157992A1 (en) 2023-05-25

Similar Documents

Publication Publication Date Title
EP3672595A4 (fr) Produit de combinaison d'un inhibiteur de bcl-2 et d'un agent chimiothérapeutique et utilisation associée dans la prévention et/ou le traitement de maladies
EP3920923A4 (fr) Agents thérapeutiques et méthodes de traitement
EP3787579A4 (fr) Instruments chirurgicaux ophtalmiques et leurs procédés d'utilisation
MX2021006884A (es) Compuestos y su uso para el tratamiento de la deficiencia de alfa1-antitripsina.
EP4106870A4 (fr) Compositions et utilisations thérapeutiques de cannabidiol
IL299245A (en) LAIR-1 binding agents and methods of using them
EP3927267A4 (fr) Dispositifs de modification de tissu de vaisseau périphérique et procédés d'utilisation associés
EP4054713A4 (fr) Compositions et méthodes de traitement ou de prévention de maladies et de troubles cutanés au moyen de lekti
EP4029504A4 (fr) Utilisation d'inhibiteur de bcl-2 et composition pharmaceutique de traitement d'une maladie de la peau liée à l'âge
EP3773266A4 (fr) Dispositifs améliorés pour le traitement de tissu et leurs procédés d'utilisation
EP4099992A4 (fr) Nouvelles formulations de cannabinoïdes et leur utilisation pour le traitement de la myélite flasque aiguë
EP4100029A4 (fr) Compositions et procédés pour les utiliser pour le traitement de la mammite
EP3737381A4 (fr) Dispositif médical et composition pharmaceutique pour le traitement d'une maladie ou affection de l'oeil
EP4121038A4 (fr) Compositions et méthodes pour le traitement d'une infection à coronavirus et d'un compromis respiratoire
EP4084869A4 (fr) Composition et thérapie pour le traitement de réflexes nauséeux
PT3937949T (pt) Fitoecdisonas e seus derivados para utilização no tratamento da alteração da função respiratória
EP4017496A4 (fr) Formulations destinées à être utilisée dans la prévention et/ou le traitement de neuropathie périphérique et ses maladies associées
GB202002299D0 (en) Agents for use in the treatment of tissue damage
MX2021015338A (es) Composicion que comprende pridopidina y un analogo de la misma para el tratamiento de la enfermedad de huntington y sintomas de la misma.
EP4122474A4 (fr) Utilisation de mitochondries pour le traitement et/ou la prévention des lésions tendineuses ou de maladies associées
PL3797771T3 (pl) Rebamipid do stosowania w zapobieganiu i leczeniu celiakii
ZA201905959B (en) Neutral endopeptidase (nep) and human soluble endopeptidase (hsep) inhibitors for prophylaxis and treatment of eye diseases
GB2610895B (en) Composition for use in the treatment and/or prevention of mycotoxic disease
GEP20207136B (en) Antiseptic composition comprising polyvinylpyrrolidone and unithiol and use of the composition
GB202107297D0 (en) Composition for use in the treatment and/or prevention of mycotoxic disease

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220908

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40078209

Country of ref document: HK

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0031047000

Ipc: A61K0031352000

A4 Supplementary search report drawn up and despatched

Effective date: 20240201

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/343 20060101ALI20240126BHEP

Ipc: A61K 31/192 20060101ALI20240126BHEP

Ipc: A61K 31/05 20060101ALI20240126BHEP

Ipc: A61P 25/02 20060101ALI20240126BHEP

Ipc: A61K 31/191 20060101ALI20240126BHEP

Ipc: A61K 31/047 20060101ALI20240126BHEP

Ipc: A61K 31/352 20060101AFI20240126BHEP